SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-043670
Filing Date
2022-04-07
Accepted
2022-04-07 17:00:51
Documents
16
Period of Report
2022-04-06
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm228420d7_8k.htm   iXBRL 8-K 31566
2 EXHIBIT 16.1 tm228420d7_ex16-1.htm EX-16.1 2851
3 EXHIBIT 99.1 tm228420d7_ex99-1.htm EX-99.1 21452
7 GRAPHIC tm228420d7_ex99-1img001.jpg GRAPHIC 5462
8 GRAPHIC tm228420d7_ex16-1img001.jpg GRAPHIC 5053
  Complete submission text file 0001104659-22-043670.txt   256781

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vyne-20220406.xsd EX-101.SCH 3060
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20220406_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20220406_pre.xml EX-101.PRE 22613
10 EXTRACTED XBRL INSTANCE DOCUMENT tm228420d7_8k_htm.xml XML 3708
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 22814544
SIC: 2834 Pharmaceutical Preparations